Aneesha Dasgupta

Aneesha Dasgupta

Auto-generated profile, based on publicly available information

Aneesha Dasgupta

Cell Biology and Physiology, Indiana University School of Medicine 1 Department of Anatomy Indianapolis, IN

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2020 in Cancer Letters
Verified
Journal Article
Closed access
SSSurendra K. Shukla
Surendra K. Shukla
SMSpas D. Markov
Spas D. Markov
KAKuldeep S. Attri
Kuldeep S. Attri
EVEnza Vernucci
Enza Vernucci
RKRyan J. King
Ryan J. King
KMKamiya Mehla
Kamiya Mehla

6 July 2020 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
ADAneesha Dasgupta
Aneesha Dasgupta
SSSurendra K. Shukla
Surendra K. Shukla
EVEnza Vernucci
Enza Vernucci
RKRyan J. King
Ryan J. King
JAJaime Abrego
Jaime Abrego
PSPankaj Singh
Pankaj Singh
Approximately one third of cancer patients die due to complexities related to cachexia. However, the mechanisms of cachexia and the potential therapeutic interventions remain poorly studied. We observed a significant positive correlation between SIRT1 expression and muscle fiber cross-sectional area in pancreatic cancer patients. Rescuing Sirt1 expression by exogenous expression or pharmacological agents reverted cancer cell–induced myotube wasting in culture conditions and mouse models. RNA-seq and follow-up analyses showed cancer cell–mediated SIRT1 loss induced NF-κB signaling in cachectic muscles that enhanced the expression of FOXO transcription factors and NADPH oxidase 4 (Nox4), a key regulator of reactive oxygen species production. Additionally, we observed a negative correlation between NOX4 expression and skeletal muscle fiber cross-sectional area in pancreatic cancer patients. Knocking out Nox4 in skeletal muscles or pharmacological blockade of Nox4 activity abrogated tumor-induced cachexia in mice. Thus, we conclude that targeting the Sirt1–Nox4 axis in muscles is an effective therapeutic intervention for mitigating pancreatic cancer–induced cachexia.

16 August 2023 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
ADAneesha Dasgupta
Aneesha Dasgupta
DGDaniel F. Gibbard
Daniel F. Gibbard
RSRebecca E. Schmitt
Rebecca E. Schmitt
PAPaige C. Arneson-Wissink
Paige C. Arneson-Wissink
ADAlexandra M. Ducharme
Alexandra M. Ducharme
JDJason D. Doles
Jason D. Doles
Cancer cachexia, and its associated complications, represent a large and currently untreatable roadblock to effective cancer management. Many potential therapies have been proposed and tested—including appetite stimulants, targeted cytokine blockers, and nutritional supplementation—yet highly effective therapies are lacking. Innovative approaches to treating cancer cachexia are needed. Members of the Kruppel-like factor (KLF) family play wide-ranging and important roles in the development, maintenance, and metabolism of skeletal muscle. Within the KLF family, we identified KLF10 upregulation in a multitude of wasting contexts—including in pancreatic, lung, and colon cancer mouse models as well as in human patients. We subsequently interrogated loss-of-function of KLF10 as a potential strategy to mitigate cancer associated muscle wasting. In vivo studies leveraging orthotopic implantation of pancreas cancer cells into wild-type and KLF10 KO mice revealed significant preservation of lean mass and robust suppression of pro-atrophy muscle-specific ubiquitin ligases Trim63 and Fbxo32, as well as other factors implicated in atrophy, calcium signaling, and autophagy. Bioinformatics analyses identified Transforming growth factor beta (TGF-β), a known inducer of KLF10 and cachexia promoting factor, as a key upstream regulator of KLF10. We provide direct in vivo evidence that KLF10 KO mice are resistant to the atrophic effects of TGF-β. ChIP-based binding studies demonstrated direct binding to Trim63 , a known wasting-associated atrogene. Taken together, we report a critical role for the TGF-β/KLF10 axis in the etiology of pancreatic cancer–associated muscle wasting and highlight the utility of targeting KLF10 as a strategy to prevent muscle wasting and limit cancer-associated cachexia.

2 July 2025 in Journal of Experimental Medicine
Verified
Journal Article
Closed access
ADAneesha Dasgupta
Aneesha Dasgupta
RSRebecca E. Schmitt
Rebecca E. Schmitt
TKTatsuyoshi Kono
Tatsuyoshi Kono
CLChih-Chun Lee
Chih-Chun Lee
MZMark I. Zoberi
Mark I. Zoberi
JDJason Doles
Jason Doles
Cancer cachexia is a multifactorial syndrome involving muscle and fat wasting, inflammation, and metabolic dysfunction. Across cancer subtypes, pancreatic cancer has one of the highest cachexia incidence rates at ∼80%. Given the advanced age of most pancreatic cancer patients, we sought to query cancer-associated muscle wasting using an age-matched murine model. We found that histamine and histamine decarboxylase (HDC) activity were specifically elevated in the muscles of aged tumor-bearing mice. We further found that (1) wasting stimuli induced histamine production and enhanced HDC activity; (2) exogenous histamine was sufficient to induce atrophy-associated gene expression; (3) inhibition of HDC activity by α-fluoromethylhistidine (FMH) protected against atrophy; (4) treatment of tumor-bearing mice with FMH rescued muscle wasting; and (5) a calcineurin inhibitor was able to rescue histamine-associated increases in calcium/atrogene signaling. In summary, we present a novel metabolic pathway that has significant implications for the treatment of cachectic cancer patients.

15 July 2024 in Current Opinion in Supportive & Palliative Care
Verified
Journal Article
Closed access
SESavannah A. Epstein
Savannah A. Epstein
JDJason D. Doles
Jason D. Doles
ADAneesha Dasgupta
Aneesha Dasgupta
Purpose of the review: Cancer-associated cachexia is a wasting syndrome entailing loss in body mass and a shortened life expectancy. There is currently no effective treatment to abrogate this syndrome, which leads to 20–30% of deaths in patients with cancer. While there have been advancements in defining signaling factors/pathways in cancer-induced muscle wasting, targeting the same in the clinic has not been as successful. Krüppel-like factor 10 (KLF10), a transcription factor implicated in muscle regulation, is regulated by the transforming growth factor-beta signaling pathway. This review proposes KLF10 as a potential convergence point of diverse signaling pathways involved in muscle wasting. Recent findings: KLF10 was discovered as a target of transforming growth factor-beta decades ago but more recently it has been shown that deletion of KLF10 rescues cancer-induced muscle wasting. Moreover, KLF10 has also been shown to bind key atrophy genes associated with muscle atrophy in vitro. Summary: There is an elevated need to explore targets in cachexia, which will successfully translate into the clinic. Investigating a convergence point downstream of multiple signaling pathways might hold promise in developing effective therapies for cachexia.

1 July 2026 in JCSM Communications
Verified
Journal Article
Open access
DGDaniel F. Gibbard
Daniel F. Gibbard
RSRebecca E. Schmitt
Rebecca E. Schmitt
AHAndrew J. Hennigan
Andrew J. Hennigan
ADAneesha Dasgupta
Aneesha Dasgupta
JSJessica Z. Schneider
Jessica Z. Schneider
JDJason Doles
Jason Doles
Background: Volumetric muscle loss (VML) is a major muscle injury that significantly impacts quality of life in affected individuals. This substantial loss of muscle tissue leads to various complications including reduced force output, impaired muscle regeneration and long‐term mobility issues. Although skeletal muscle is typically a highly regenerative tissue, damage beyond a critical threshold prevents full recovery. To better understand this limitation, we investigated the differences between more regenerative (healing) and less regenerative (nonhealing) muscle in a murine model of VML. Methods: We used longitudinal strength measurements, transcriptomic analyses and bioinformatics to assess differences between injury (defect) sizes. These approaches were used to assess functional recovery and to identify molecular and metabolic features associated with healing versus nonhealing injuries. Results: Our results showed that 2‐mm VML defects led to reduced force outputs at 7 and 14 days of postinjury but recovered to baseline levels by 28 days—indicating healing. In contrast, mice with 4‐mm VML injuries failed to recover force output by 28 days—representing a nonhealing response. Transcriptomic and bioinformatic analyses revealed that nonhealing injuries exhibited prolonged activation of healing‐associated pathways. Mitochondria‐related transcript signatures were most strongly correlated with both strength loss and defect size. Additionally, we observed metabolic alterations at the whole muscle level via a shift in myofiber isotype composition—specifically a reduction in fast, glycolytic type IIB myofibers and an increase in oxidative type IIA myofibers. Conclusions: These findings highlight the critical role of mitochondrial function and metabolic rewiring in determining regenerative outcomes following VML injury. Differences in mitochondrial activity, protein expression and myofiber composition distinguish healing from nonhealing defects and may explain why larger injuries fail to fully recover.